Renal cell neoplasias: Reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Rabien, Anja ^a   Stephan, Carsten ^a,b   Kilic, Ergin ^a   Weichert, Wilko ^c   Kristiansen, Glen ^d   Miller, Kurt ^a   Jung, Klaus ^a,b   Erbersdobler, Andreas ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

EMMPRIN; RECK; Renal cell carcinoma; TMA

Indexed keywords

CD147 ANTIGEN; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME LOCALIZATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; ONCOCYTOMA; OVERALL SURVIVAL; PATHOGENESIS; RETROSPECTIVE STUDY; STAINING; SURVIVAL PREDICTION; TISSUE MICROARRAY; TUMOR INVASION; WESTERN BLOTTING;

ANTIGENS, CD147; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; FEMALE; GPI-LINKED PROTEINS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; TISSUE ARRAY ANALYSIS;

EID: 84885464108     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-258     Document Type: Article

References (23)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Fornara P, Hoda MR. [Renal cell carcinoma]. Urologe A 2011, 50(Suppl 1):219-222.
3. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406. 10.1016/j.eururo.2010.06.032, 20633979.
4. Moch H. An overview of renal cell cancer: pathology and genetics. Semin Cancer Biol 2013, 23:3-9. 10.1016/j.semcancer.2012.06.006, 22722066.
5. Shen SS, Truong LD, Scarpelli M, Lopez-Beltran A. Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful?. Arch Pathol Lab Med 2012, 136:410-417. 10.5858/arpa.2011-0472-RA, 22458903.
6. Wittschieber D, Stenzinger A, Klauschen F, Stephan C, Jung K, Erbersdobler A, Rabien A. Decreased RECK and increased EMMPRIN expression in urothelial carcinoma of the bladder Are associated with tumor aggressiveness. Pathobiology 2011, 78:123-131. 10.1159/000323563, 21613799.
7. Han ZD, He HC, Bi XC, Qin WJ, Dai QS, Zou J, Ye YK, Liang YX, Zeng GH, Zhu G, et al. Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res 2010, 160:260-267. 10.1016/j.jss.2008.11.838, 19286191.
8. Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF, Lee WH. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 2006, 13:573-580. 10.1111/j.1442-2042.2006.01353.x, 16771728.
9. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K. High incidence of EMMPRIN expression in human tumors. Int J Cancer 2006, 119:1800-1810. 10.1002/ijc.22062, 16721788.
10. Tsai WC, Sheu LF, Nieh S, Yu CP, Sun GH, Lin YF, Chen A, Jin JS. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. World J Urol 2007, 25:73-80. 10.1007/s00345-006-0110-2, 17021824.
11. Wittekind C, Meyer HJ. TNM classification of malignant tumours, 7th 2010, New York: Wiley-Liss.
12. Simizu S, Takagi S, Tamura Y, Osada H. RECK-mediated suppression of tumor cell invasion is regulated by glycosylation in human tumor cell lines. Cancer Res 2005, 65:7455-7461. 10.1158/0008-5472.CAN-04-4446, 16103099.
13. Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ, Li Y. The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 2008, 57:1367-1379. 10.1007/s00262-008-0473-x, 18273614.
14. Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Eur Urol 2007, 51:1259-1266. 10.1016/j.eururo.2006.05.050, 16806661.
15. Stenzinger A, von Winterfeld M, Rabien A, Warth A, Kamphues C, Dietel M, Weichert W, Klauschen F, Wittschieber D. Reversion-inducing cysteine-rich protein with kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer. Hum Pathol 2012, 43:1314-1321. 10.1016/j.humpath.2011.10.012, 22397871.
16. Stenzinger A, Wittschieber D, von Winterfeld M, Goeppert B, Kamphues C, Weichert W, Dietel M, Rabien A, Klauschen F. High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer. Hum Pathol 2012, 43:1471-1481. 10.1016/j.humpath.2011.10.023, 22417846.
17. Shimada M, Yamabe H, Osawa H, Nakamura N, Kumasaka R, Murakami R, Fujita T, Osanai T, Okumura K. Extracellular matrix metalloproteinase inducer is expressed in the proximal tubular epithelial cells of the human kidney. Nephrol (Carlton) 2009, 14:171-178.
18. Liang YX, He HC, Han ZD, Bi XC, Dai QS, Ye YK, Qin WJ, Zeng GH, Zhu G, Xu CL, et al. CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value. Cancer Invest 2009, 27:788-793. 10.1080/07357900802709167, 19548138.
19. Rabien A, Ergun B, Erbersdobler A, Jung K, Stephan C. RECK overexpression decreases invasive potential in prostate cancer cells. Prostate 2012, 72:948-954. 10.1002/pros.21498, 22025325.
20. Clark JC, Thomas DM, Choong PF, Dass CR. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007, 26:675-683. 10.1007/s10555-007-9093-8, 17828469.
21. Noda M, Takahashi C. Recklessness as a hallmark of aggressive cancer. Cancer Sci 2007, 98:1659-1665. 10.1111/j.1349-7006.2007.00588.x, 17725805.
22. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490. 10.1056/NEJMra043172, 16339096.
23. Storkel S, Steart PV, Drenckhahn D, Thoenes W. The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol 1989, 56:237-245.